Business Context and Reporting Period
This Form 6-K was furnished by NLS Pharmaceutics Ltd., a Swiss foreign private issuer, for the month of October 2022. The filing reports the results of an extraordinary shareholders’ meeting held on October 27, 2022, and the filing of amended and restated articles of association on October 28, 2022.
The request metadata identifies the company as Newcelx Ltd.; however, the filing text identifies the registrant as NLS Pharmaceutics Ltd.
Key Financial and Capitalization Information
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or operating performance metrics.
- Outstanding share capital increased to CHF 586,998.86, divided into 29,349,943 registered shares.
- Authorized share capital permits issuance of up to CHF 293,499.42 through 14,674,971 additional registered shares until October 27, 2024.
- Conditional share capital for employee and advisory options permits issuance of up to CHF 42,182 through 2,109,100 registered shares.
- Conditional share capital for shareholder options permits issuance of up to CHF 251,317.42 through 12,565,871 registered shares.
Material Changes Versus the Prior Comparable Period
- The filing does not present a prior-period financial comparison.
- The principal reported changes are the increase in outstanding share capital and the establishment or amendment of authorized and conditional share capital provisions in the amended articles.
- Shareholders approved all agenda items described in the notice of meeting and proxy statement.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operating outlook, management forecast, or discussion of business risks or contingencies.
The authorized and conditional share capital provisions could result in future share issuances and dilution, depending on whether the company exercises the authorizations or options. The filing does not state the timing, pricing, or intended use of any potential issuance.
The report was incorporated by reference into the company’s Form F-3 registration statement, File No. 333-262489, to the extent not superseded by subsequent filings.
Investor Verification Items
- Verify the registrant’s identity, since the source filing names NLS Pharmaceutics Ltd., while the request metadata names Newcelx Ltd.
- Review Exhibit 3.1 for the complete amended and restated articles of association.
- Confirm the final outstanding share count and the terms, exercise periods, and potential dilution associated with the authorized and conditional share capital.
- Review subsequent SEC filings for any share issuances, option exercises, financing transactions, or amendments to the capital structure.